The U.S. Veterans Health Administration will pay for some beneficiaries to get a new Alzheimer's disease drug from Eisai Co. and Biogen Inc., a move toward broader coverage of the controversial drug category.The VA added Leqembi, which received accelerated approval from the Food and Drug Administration in January, to its list of nonformulary drugs.
[
add
]
[
|
|
...
]